Literature DB >> 24304083

Value-engineered translation for regenerative medicine: meeting the needs of health systems.

Tania Bubela1, Christopher McCabe.   

Abstract

Despite high expectations of economic returns, large investments in regenerative medicine technology have yet to materialize, partly due to a lack of proven business and investment models, regulatory hurdles, and a greater focus on cost-effectiveness for reimbursement decisions by payors. Adoption of new economic modeling methods will better link investment decisions to value-based criteria of health systems.

Entities:  

Mesh：

Year:  2013        PMID： 24304083      PMCID： PMC3883180          DOI： 10.1089/scd.2013.0398

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN： 1547-3287            Impact factor:   3.272


  30 in total

1.  Expected net present value of sample information: from burden to investment.

Authors:  Peter S Hall; Richard Edlin; Samer Kharroubi; Walter Gregory; Christopher McCabe
Journal:  Med Decis Making       Date:  2012-04-30       Impact factor: 2.583

2.  Stem cell research and economic promises.

Authors:  Timothy Caulfield
Journal:  J Law Med Ethics       Date:  2010       Impact factor: 1.718

3.  The challenges of regulating stem cell-based products.

Authors:  Barbara J von Tigerstrom
Journal:  Trends Biotechnol       Date:  2008-10-30       Impact factor: 19.536

Review 4.  Societal values in the allocation of healthcare resources: is it all about the health gain?

Authors:  Tania Stafinski; Devidas Menon; Deborah Marshall; Timothy Caulfield
Journal:  Patient       Date:  2011       Impact factor: 3.883

Review 5.  The NICE cost-effectiveness threshold: what it is and what that means.

Authors:  Christopher McCabe; Karl Claxton; Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  An investment appraisal approach to clinical trial design.

Authors:  M E Backhouse
Journal:  Health Econ       Date:  1998-11       Impact factor: 3.046

7.  Cell therapy industry: billion dollar global business with unlimited potential.

Authors:  Chris Mason; David A Brindley; Emily J Culme-Seymour; Natasha L Davie
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

8.  Engaging the public in priority-setting for health technology assessment: findings from a citizens' jury.

Authors:  Devidas Menon; Tania Stafinski
Journal:  Health Expect       Date:  2008-09       Impact factor: 3.377

Review 9.  The promise and perils of stem cell therapeutics.

Authors:  George Q Daley
Journal:  Cell Stem Cell       Date:  2012-06-14       Impact factor: 24.633

10.  Probabilistic analysis and computationally expensive models: Necessary and required?

Authors:  Susan Griffin; Karl Claxton; Neil Hawkins; Mark Sculpher
Journal:  Value Health       Date:  2006 Jul-Aug       Impact factor: 5.725
View more
  2 in total

Review 1.  Mesenchymal stem cells in neurodegenerative diseases: Opinion review on ethical dilemmas.

Authors:  Matteo Scopetti; Alessandro Santurro; Vittorio Gatto; Raffaele La Russa; Federico Manetti; Stefano D'Errico; Paola Frati; Vittorio Fineschi
Journal:  World J Stem Cells       Date:  2020-03-26       Impact factor: 5.326

Review 2.  A blueprint for translational regenerative medicine.

Authors:  James P K Armstrong; Timothy J Keane; Anne C Roques; P Stephen Patrick; Claire M Mooney; Wei-Li Kuan; Venkat Pisupati; Richard O C Oreffo; Daniel J Stuckey; Fiona M Watt; Stuart J Forbes; Roger A Barker; Molly M Stevens
Journal:  Sci Transl Med       Date:  2020-12-02       Impact factor: 17.956
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.